Platform Technology Partners’s Moderna MRNA Stock Holding History

Platform Technology Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$232K	Buy	+1,203	New	+$130K	0.04%	334

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Platform Technology Partners's MRNA Position: Q3 2026 in Review

Platform Technology Partners opened a new position in Moderna (MRNA) in Q3 2026: 1,203 shares worth $232K. The stake represents 0.04% of the portfolio and ranks #334 among its holdings.

633 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Platform Technology Partners held 1,203 shares of Moderna worth $232K as of Q3 2026.
Moderna was a new Platform Technology Partners position in Q3 2026.
Moderna made up 0.04% of Platform Technology Partners's portfolio in Q3 2026, its #334 holding.
633 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Platform Technology Partners's 13F filing for Q3 2026, filed 2 Nov 2026.